# Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years

## TL;DR

This paper discusses how genomic medicine and digital health can improve care for primary immunodeficiency patients while addressing challenges in access and collaboration.

## Contribution

The paper provides actionable recommendations for advancing PID care through global collaboration and real-world evidence-based treatments.

## Key findings

- Genomic medicine and digital health are identified as key areas for improving PID treatment.
- Collaboration among stakeholders is crucial for minimizing risks and ensuring patient access to care.
- Recommendations focus on real-world evidence and patient-centered treatment approaches.

## Abstract

The International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders’ Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration.

This edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care.

These discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years.

These discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient’s needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.